KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $35.6 million.

  • Biomarin Pharmaceutical's Net Cash Flow rose 11210.1% to $35.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $575.9 million, marking a year-over-year increase of 63007.13%. This contributed to the annual value of $182.9 million for FY2024, which is 52443.66% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Net Cash Flow of $35.6 million as of Q3 2025, which was up 11210.1% from $168.1 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Net Cash Flow high stood at $264.9 million for Q4 2024, and its period low was -$293.8 million during Q3 2024.
  • Over the past 5 years, Biomarin Pharmaceutical's median Net Cash Flow value was $17.1 million (recorded in 2022), while the average stood at $31.5 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Net Cash Flow crashed by 94755.43% in 2023, and later skyrocketed by 116757.8% in 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Net Cash Flow (Quarter) stood at -$29.8 million in 2021, then fell by 24.16% to -$37.1 million in 2022, then increased by 28.11% to -$26.6 million in 2023, then surged by 1094.33% to $264.9 million in 2024, then tumbled by 86.58% to $35.6 million in 2025.
  • Its last three reported values are $35.6 million in Q3 2025, $168.1 million for Q2 2025, and $107.4 million during Q1 2025.